ATR vs. WAT: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ATR and WAT, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
WAT’s market capitalization of 20.84 billion USD is significantly greater than ATR’s 10.64 billion USD, highlighting its more substantial market valuation.
WAT carries a higher beta at 1.12, indicating it’s more sensitive to market moves, while ATR (beta: 0.59) exhibits greater stability.
| Symbol | ATR | WAT |
|---|---|---|
| Company Name | AptarGroup, Inc. | Waters Corporation |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Instruments & Supplies | Medical - Diagnostics & Research |
| CEO | Stephan B. Tanda | Udit Batra |
| Price | 161.04 USD | 350.22 USD |
| Market Cap | 10.64 billion USD | 20.84 billion USD |
| Beta | 0.59 | 1.12 |
| Exchange | NYSE | NYSE |
| IPO Date | April 23, 1993 | November 17, 1995 |
| ADR | No | No |
Historical Performance
This chart compares the performance of ATR and WAT by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ATR
14.87%
Medical - Instruments & Supplies Industry
- Max
- 26.65%
- Q3
- 13.00%
- Median
- 1.08%
- Q1
- -8.11%
- Min
- -38.20%
In the upper quartile for the Medical - Instruments & Supplies industry, ATR’s Return on Equity of 14.87% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
WAT
38.61%
Medical - Diagnostics & Research Industry
- Max
- 57.35%
- Q3
- 18.17%
- Median
- 2.69%
- Q1
- -16.72%
- Min
- -48.78%
In the upper quartile for the Medical - Diagnostics & Research industry, WAT’s Return on Equity of 38.61% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Return on Invested Capital
ATR
11.90%
Medical - Instruments & Supplies Industry
- Max
- 20.14%
- Q3
- 7.36%
- Median
- 1.97%
- Q1
- -6.22%
- Min
- -20.00%
In the upper quartile for the Medical - Instruments & Supplies industry, ATR’s Return on Invested Capital of 11.90% signifies a highly effective use of its capital to generate profits when compared to its peers.
WAT
18.90%
Medical - Diagnostics & Research Industry
- Max
- 42.99%
- Q3
- 11.55%
- Median
- 3.02%
- Q1
- -11.49%
- Min
- -40.79%
In the upper quartile for the Medical - Diagnostics & Research industry, WAT’s Return on Invested Capital of 18.90% signifies a highly effective use of its capital to generate profits when compared to its peers.
Net Profit Margin
ATR
10.42%
Medical - Instruments & Supplies Industry
- Max
- 28.95%
- Q3
- 11.24%
- Median
- -2.83%
- Q1
- -12.85%
- Min
- -26.41%
ATR’s Net Profit Margin of 10.42% is aligned with the median group of its peers in the Medical - Instruments & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.
WAT
22.02%
Medical - Diagnostics & Research Industry
- Max
- 22.76%
- Q3
- 15.19%
- Median
- 1.64%
- Q1
- -22.25%
- Min
- -78.24%
A Net Profit Margin of 22.02% places WAT in the upper quartile for the Medical - Diagnostics & Research industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin
ATR
14.17%
Medical - Instruments & Supplies Industry
- Max
- 32.10%
- Q3
- 16.03%
- Median
- 2.28%
- Q1
- -7.96%
- Min
- -26.84%
ATR’s Operating Profit Margin of 14.17% is around the midpoint for the Medical - Instruments & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
WAT
28.37%
Medical - Diagnostics & Research Industry
- Max
- 36.06%
- Q3
- 20.26%
- Median
- 6.15%
- Q1
- -21.89%
- Min
- -82.21%
An Operating Profit Margin of 28.37% places WAT in the upper quartile for the Medical - Diagnostics & Research industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | ATR | WAT |
|---|---|---|
| Return on Equity (TTM) | 14.87% | 38.61% |
| Return on Assets (TTM) | 8.18% | 14.31% |
| Return on Invested Capital (TTM) | 11.90% | 18.90% |
| Net Profit Margin (TTM) | 10.42% | 22.02% |
| Operating Profit Margin (TTM) | 14.17% | 28.37% |
| Gross Profit Margin (TTM) | 36.41% | 62.08% |
Financial Strength
Current Ratio
ATR
1.25
Medical - Instruments & Supplies Industry
- Max
- 6.79
- Q3
- 4.57
- Median
- 2.64
- Q1
- 1.81
- Min
- 1.10
ATR’s Current Ratio of 1.25 falls into the lower quartile for the Medical - Instruments & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
WAT
1.81
Medical - Diagnostics & Research Industry
- Max
- 6.91
- Q3
- 4.11
- Median
- 2.46
- Q1
- 1.44
- Min
- 0.73
WAT’s Current Ratio of 1.81 aligns with the median group of the Medical - Diagnostics & Research industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
ATR
0.41
Medical - Instruments & Supplies Industry
- Max
- 1.46
- Q3
- 0.74
- Median
- 0.41
- Q1
- 0.16
- Min
- 0.03
ATR’s Debt-to-Equity Ratio of 0.41 is typical for the Medical - Instruments & Supplies industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
WAT
0.78
Medical - Diagnostics & Research Industry
- Max
- 1.10
- Q3
- 0.82
- Median
- 0.39
- Q1
- 0.21
- Min
- 0.01
WAT’s Debt-to-Equity Ratio of 0.78 is typical for the Medical - Diagnostics & Research industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio
ATR
11.17
Medical - Instruments & Supplies Industry
- Max
- 25.04
- Q3
- 8.80
- Median
- 3.66
- Q1
- -3.85
- Min
- -11.93
ATR’s Interest Coverage Ratio of 11.17 is in the upper quartile for the Medical - Instruments & Supplies industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
WAT
16.97
Medical - Diagnostics & Research Industry
- Max
- 37.07
- Q3
- 5.62
- Median
- 1.76
- Q1
- -38.78
- Min
- -57.46
WAT’s Interest Coverage Ratio of 16.97 is in the upper quartile for the Medical - Diagnostics & Research industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | ATR | WAT |
|---|---|---|
| Current Ratio (TTM) | 1.25 | 1.81 |
| Quick Ratio (TTM) | 0.85 | 1.28 |
| Debt-to-Equity Ratio (TTM) | 0.41 | 0.78 |
| Debt-to-Asset Ratio (TTM) | 0.23 | 0.33 |
| Net Debt-to-EBITDA Ratio (TTM) | 1.19 | 1.16 |
| Interest Coverage Ratio (TTM) | 11.17 | 16.97 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ATR and WAT. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ATR
1.12%
Medical - Instruments & Supplies Industry
- Max
- 4.02%
- Q3
- 0.38%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 1.12%, ATR offers a more attractive income stream than most of its peers in the Medical - Instruments & Supplies industry, signaling a strong commitment to shareholder returns.
WAT
0.00%
Medical - Diagnostics & Research Industry
- Max
- 2.76%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
WAT currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio
ATR
31.58%
Medical - Instruments & Supplies Industry
- Max
- 76.77%
- Q3
- 11.37%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ATR’s Dividend Payout Ratio of 31.58% is in the upper quartile for the Medical - Instruments & Supplies industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
WAT
0.00%
Medical - Diagnostics & Research Industry
- Max
- 37.46%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
WAT has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ATR | WAT |
|---|---|---|
| Dividend Yield (TTM) | 1.12% | 0.00% |
| Dividend Payout Ratio (TTM) | 31.58% | 0.00% |
Valuation
Price-to-Earnings Ratio
ATR
28.83
Medical - Instruments & Supplies Industry
- Max
- 45.65
- Q3
- 44.10
- Median
- 35.47
- Q1
- 29.60
- Min
- 21.65
In the lower quartile for the Medical - Instruments & Supplies industry, ATR’s P/E Ratio of 28.83 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
WAT
31.68
Medical - Diagnostics & Research Industry
- Max
- 48.28
- Q3
- 44.64
- Median
- 29.13
- Q1
- 22.34
- Min
- 15.59
WAT’s P/E Ratio of 31.68 is within the middle range for the Medical - Diagnostics & Research industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Forward P/E to Growth Ratio
ATR
2.54
Medical - Instruments & Supplies Industry
- Max
- 5.80
- Q3
- 3.68
- Median
- 2.56
- Q1
- 1.87
- Min
- 0.22
ATR’s Forward PEG Ratio of 2.54 is within the middle range of its peers in the Medical - Instruments & Supplies industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
WAT
3.23
Medical - Diagnostics & Research Industry
- Max
- 4.18
- Q3
- 3.64
- Median
- 2.40
- Q1
- 0.57
- Min
- 0.04
WAT’s Forward PEG Ratio of 3.23 is within the middle range of its peers in the Medical - Diagnostics & Research industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
Price-to-Sales Ratio
ATR
2.99
Medical - Instruments & Supplies Industry
- Max
- 12.87
- Q3
- 6.95
- Median
- 3.45
- Q1
- 2.24
- Min
- 0.71
ATR’s P/S Ratio of 2.99 aligns with the market consensus for the Medical - Instruments & Supplies industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
WAT
6.99
Medical - Diagnostics & Research Industry
- Max
- 12.53
- Q3
- 6.19
- Median
- 3.58
- Q1
- 1.95
- Min
- 0.58
WAT’s P/S Ratio of 6.99 is in the upper echelon for the Medical - Diagnostics & Research industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio
ATR
4.18
Medical - Instruments & Supplies Industry
- Max
- 9.60
- Q3
- 5.48
- Median
- 3.37
- Q1
- 1.95
- Min
- 0.65
ATR’s P/B Ratio of 4.18 is within the conventional range for the Medical - Instruments & Supplies industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
WAT
10.61
Medical - Diagnostics & Research Industry
- Max
- 10.67
- Q3
- 5.74
- Median
- 2.95
- Q1
- 1.30
- Min
- 0.39
The P/B Ratio is often not a primary valuation metric for the Medical - Diagnostics & Research industry.
Valuation at a Glance
| Symbol | ATR | WAT |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 28.83 | 31.68 |
| Forward PEG Ratio (TTM) | 2.54 | 3.23 |
| Price-to-Sales Ratio (P/S, TTM) | 2.99 | 6.99 |
| Price-to-Book Ratio (P/B, TTM) | 4.18 | 10.61 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 29.67 | 33.66 |
| EV-to-EBITDA (TTM) | 14.80 | 22.10 |
| EV-to-Sales (TTM) | 3.25 | 7.37 |